All In Biotech

Drug Trial Radar · NCT04053764

Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell Disease

A Phase II, Multicenter, Randomized, Open Label Two Arm Study Evaluating the Effect of Crizanlizumab + Standard of Care and Standard of Care Alone on Renal Function in Sickle Cell Disease Patients ≥ 16 Years With Chronic Kidney Disease Due to Sickle Cell Nephropathy (STEADFAST)

Last checked: Nov 20, 2026Latest source record: Oct 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

58

Actual

Start

Dec 10, 2019

Primary completion

Mar 20, 2023

Study completion Mar 20, 2023

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Aug 12, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of the study was to evaluate descriptively the effect of crizanlizumab + standard of care and standard of care alone on renal function in sickle cell disease patients ≥ 16 years with chronic kidney disease due to sickle cell nephropathy.

Conditions

  • Sickle Cell Disease (SCD)

Interventions

  • CrizanlizuambDrug

    Crizanlizumab is a concentrate for solution for infusion, i.v. use. Supplied in single use 10 mL vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab

  • Standard of CareDrug

    HU/HC (hydroxyurea/hydroxycarbamide) and/or ACE (angiotensin-converting enzyme) inhibitors and/or ARBs (angiotensin-receptor blocker)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With ≥ 30% Decrease in Albuminuria (ACR) at 12 MonthsTime frame: Baseline to 12 months

Locations

24 sites in 11 countries. Site status is shown where the registry gives one.

  • University of Alabama Birmingham

    Birmingham, Alabama

  • University of Illinois Hospital and Health Sciences System .

    Chicago, Illinois

  • Our Lady of the Lake Regional Medic .

    Baton Rouge, Louisiana

  • East Carolina University BrodySchool of Med 3

    Greenville, North Carolina

  • Univ of Tenn Health Sciences Ctr

    Memphis, Tennessee

  • University of Texas Health Science Center at Houston

    Houston, Texas

  • Novartis Investigative Site

    Porto Alegre, Brazil

  • Novartis Investigative Site

    Rio de Janeiro, Rio de Janeiro, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil

  • Novartis Investigative Site

    Créteil, France

  • Novartis Investigative Site

    Paris, France

  • Novartis Investigative Site

    Athens, Greece

  • Novartis Investigative Site

    Larissa, Greece

  • Novartis Investigative Site

    Dublin, Ireland

  • Novartis Investigative Site

    Tripoli, Lebanon

  • Novartis Investigative Site

    Amsterdam, Netherlands

  • Novartis Investigative Site

    Panama City, Panama

  • Novartis Investigative Site

    Barcelona, Catalonia, Spain

  • Novartis Investigative Site

    Adana, Turkey (Türkiye)

  • Novartis Investigative Site

    Adana, Turkey (Türkiye)

  • Novartis Investigative Site

    Antakya / Hatay, Turkey (Türkiye)

  • Novartis Investigative Site

    London, United Kingdom

  • Novartis Investigative Site

    London, United Kingdom

  • Novartis Investigative Site

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.